RBC Capital raised the firm’s price target on Verastem (VSTM) to $16 from $13 and keeps an Outperform rating on the shares as part of a broader ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.

Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...

BTIG Research has recently reiterated Verastem Inc (VSTM) stock to Buy rating, as announced on December 31, 2024, according to Finviz. Earlier, on September 30, 2024, Guggenheim had initiated the ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

Following news that the U.S. Food and Drug Administration approved its New Drug Application for avutometinib in combination ...

Verastem (NASDAQ:VSTM) said the FDA has accepted its New Drug Application for accelerated approval of its drugs avutometinib ...

Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025 ...

On Monday, Verastem Inc (VSTM) stock saw a decline, ending the day at $3.67 which represents a decrease of $-0.04 or -1.08% from the prior close of $3.71. The stock opened at $3.62 and touched a low ...

Shares of Verastem surged after the company's new cancer treatment got priority review from regulators. The stock was up 46% at $5.37 on Tuesday. Shares are still down 35% since the start of the year.